MRNA:OTCQB-Marina Biotech Inc (USD)

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 119.22

Change

+0.38 (+0.32)%

Market Cap

USD 0.02B

Volume

3.08M

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 130.01B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.52B
ARGX argenx NV ADR

N/A

USD 32.41B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.27B
BGNE BeiGene Ltd

N/A

USD 20.54B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 17.44B
RPRX Royalty Pharma Plc

N/A

USD 17.14B
UTHR United Therapeutics Corporatio..

N/A

USD 15.72B
INSM Insmed Inc

N/A

USD 12.93B
SRPT Sarepta Therapeutics Inc

N/A

USD 12.85B

ETFs Containing MRNA

MRN3:LSE Leverage Shares 3x Long M.. 300.13 % 0.00 %

N/A

USD 0.30M
MSGR 6.26 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.70 % 0.00 %

N/A

N/A
HVAX:CA 4.95 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 4.67 % 0.00 %

N/A

N/A
GN0M:XETRA Global X Genomics & Biote.. 3.76 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.76 % 0.00 %

N/A

USD 5.87M
XNNV:XETRA Xtrackers MSCI Innovation.. 3.03 % 0.00 %

N/A

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

N/A

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

N/A

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.69 % 0.00 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 1.68 % 0.39 %

N/A

CAD 0.28B
FCTR 1.68 % 0.00 %

N/A

N/A
TAEQ 1.46 % 0.00 %

N/A

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 1.65B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.09B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.71B
BTEC 0.00 % 0.42 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.01B
LS:CA 0.00 % 2.21 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
RYH 0.00 % 0.40 %

N/A

N/A
XT iShares Exponential Techn.. 0.00 % 0.47 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
MRNS:LSE -299.96 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.86% 72% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.86% 72% C 80% B-
Trailing 12 Months  
Capital Gain 8.17% 68% D+ 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.17% 67% D+ 60% D-
Trailing 5 Years  
Capital Gain 836.53% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 836.53% 97% N/A 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 121.45% 93% A 96% N/A
Dividend Return 121.45% 93% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 218.41% 12% F 7% C-
Risk Adjusted Return 55.61% 96% N/A 82% B
Market Capitalization 0.02B 100% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector